amlodipine has been researched along with Disease Exacerbation in 44 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 7.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril." | 5.24 | Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017) |
| " Intact FGF-23, the eGFR, proteinuria and the endothelium-dependent flow-mediated (FMD) response to ischemia and other parameters were measured at baseline and after 12-weeks of treatment with ramipril (n = 68) or amlodipine (n = 32)." | 5.19 | Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. ( Cetinkaya, H; Eyileten, T; Gok, M; Karaman, M; Kurt, YG; Mallamaci, F; Oguz, Y; Saglam, M; Sonmez, A; Unal, HU; Vural, A; Yilmaz, MI; Zoccali, C, 2014) |
| "The study was a randomized controlled trial of 2 antihypertensives (amlodipine and enalapril) compared with placebo in patients with coronary artery disease and diastolic blood pressure less than 100 mm Hg." | 5.16 | Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. ( Ganz, P; Kinlay, S; Libby, P; Nicholls, SJ; Nissen, SE; Rifai, N; Sutradhar, SC; Zamani, P, 2012) |
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "Spontaneously hypertensive rats (SHR) was used to study left ventricular hypertrophy (LVH) and its dynamic change after the interventions with Telmisartan and Amlodipine." | 3.81 | TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats. ( Chen, L; Hong, H; Lin, X; Shi, X; Wu, Y; Zou, G, 2015) |
| "The results of this study suggested that the L/N-type CCB, cilnidipine, had additive antihypertensive and proteinuria-lowering effects when administered in combination with an ARB, even in type-1 diabetic rats, and that the L-type CCB, amlodipine, did not." | 3.79 | Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. ( Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T, 2013) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| " In the present study, we evaluated the effect of an ARB, olmesartan medoxomil (CS866), on the progression of peritoneal fibrosis in peritoneal dialysis by examining its effect in a model of peritoneal fibrosis in hypertensive rats." | 3.74 | Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. ( Fukushima, R; Imai, H; Ishida, Y; Nakamoto, H; Suzuki, H; Yamanouchi, Y, 2008) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 3.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Amlodipine, which has membrane-remodeling properties, is emerging as an important atheroprotective drug." | 2.41 | The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. ( Chen, M; Ferdinand, FD; Huang, Y; Laury-Kleintop, L; Sumner, AE; Tulenko, TN, 2001) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.55) | 18.2507 |
| 2000's | 25 (56.82) | 29.6817 |
| 2010's | 17 (38.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, CN | 1 |
| Soliman, EZ | 1 |
| Simpson, LM | 2 |
| Davis, BR | 2 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Bolanle, IO | 1 |
| Omogbai, EKI | 1 |
| Bafor, EE | 1 |
| Khatir, DS | 1 |
| Pedersen, M | 1 |
| Ivarsen, P | 1 |
| Christensen, KL | 1 |
| Jespersen, B | 1 |
| Buus, NH | 1 |
| Ohta, Y | 1 |
| Kawano, Y | 1 |
| Iwashima, Y | 1 |
| Hayashi, S | 1 |
| Yoshihara, F | 1 |
| Matayoshi, T | 1 |
| Takiuchi, S | 1 |
| Kamide, K | 1 |
| Nakamura, S | 1 |
| Horio, T | 1 |
| Sweiss, N | 1 |
| Sharma, K | 1 |
| Kawashiri, MA | 1 |
| Sakata, K | 1 |
| Gamou, T | 1 |
| Kanaya, H | 1 |
| Miwa, K | 1 |
| Ueda, K | 1 |
| Higashikata, T | 1 |
| Mizuno, S | 1 |
| Michishita, I | 1 |
| Namura, M | 1 |
| Nitta, Y | 1 |
| Katsuda, S | 1 |
| Okeie, K | 1 |
| Hirase, H | 1 |
| Tada, H | 1 |
| Uchiyama, K | 1 |
| Konno, T | 1 |
| Hayashi, K | 1 |
| Ino, H | 1 |
| Nagase, K | 1 |
| Terashima, M | 1 |
| Yamagishi, M | 1 |
| Zou, G | 1 |
| Hong, H | 1 |
| Lin, X | 1 |
| Shi, X | 1 |
| Wu, Y | 1 |
| Chen, L | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Saglam, M | 1 |
| Kurt, YG | 1 |
| Unal, HU | 1 |
| Karaman, M | 1 |
| Gok, M | 1 |
| Cetinkaya, H | 1 |
| Eyileten, T | 1 |
| Oguz, Y | 1 |
| Vural, A | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Borghi, C | 1 |
| Morbini, M | 1 |
| Cicero, AF | 1 |
| Whittle, J | 1 |
| Lynch, AI | 1 |
| Tanner, RM | 1 |
| Rahman, M | 1 |
| Whelton, PK | 1 |
| Oparil, S | 1 |
| Muntner, P | 1 |
| Kim, JS | 1 |
| Park, S | 1 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Cerezo, C | 1 |
| Nakamoto, H | 1 |
| Imai, H | 1 |
| Fukushima, R | 1 |
| Ishida, Y | 1 |
| Yamanouchi, Y | 1 |
| Suzuki, H | 2 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Maruyama, N | 1 |
| Matsumoto, K | 1 |
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Gholam, P | 1 |
| Sehr, T | 1 |
| Enk, A | 1 |
| Hartmann, M | 1 |
| Miyauchi, K | 1 |
| Kojima, T | 1 |
| Yokoyama, T | 1 |
| Kurata, T | 1 |
| Yokoyama, K | 1 |
| Kawamura, M | 1 |
| Suwa, S | 1 |
| Okazaki, S | 1 |
| Inoue, K | 1 |
| Fujiwara, Y | 1 |
| Sumiyoshi, M | 1 |
| Tanimoto, K | 1 |
| Nakazato, Y | 1 |
| Yamagami, S | 1 |
| Daida, H | 1 |
| Heerspink, HL | 1 |
| de Zeeuw, D | 1 |
| Bakris, GL | 1 |
| Sarafidis, PA | 1 |
| Weir, MR | 1 |
| Dahlöf, B | 1 |
| Pitt, B | 2 |
| Jamerson, K | 2 |
| Velazquez, EJ | 1 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 1 |
| Shi, V | 1 |
| Chiang, YT | 1 |
| Weber, MA | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 1 |
| Tsutsumi, A | 1 |
| Kim-Mitsuyama, S | 1 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 1 |
| Zamani, P | 1 |
| Ganz, P | 1 |
| Libby, P | 1 |
| Sutradhar, SC | 1 |
| Rifai, N | 1 |
| Nicholls, SJ | 1 |
| Nissen, SE | 1 |
| Kinlay, S | 1 |
| Aritomi, S | 1 |
| Niinuma, K | 1 |
| Ogawa, T | 1 |
| Konda, T | 1 |
| Nitta, K | 1 |
| Mancini, GB | 2 |
| Wright, JT | 1 |
| Bakris, G | 1 |
| Greene, T | 1 |
| Agodoa, LY | 1 |
| Appel, LJ | 1 |
| Charleston, J | 1 |
| Cheek, D | 1 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 1 |
| Glassock, R | 1 |
| Hebert, L | 1 |
| Lewis, J | 1 |
| Phillips, RA | 1 |
| Toto, RD | 1 |
| Middleton, JP | 1 |
| Rostand, SG | 1 |
| Fukuda, M | 1 |
| Usami, T | 1 |
| Yoshida, A | 1 |
| Kimura, G | 1 |
| Palmer, AJ | 2 |
| Annemans, L | 1 |
| Roze, S | 1 |
| Lamotte, M | 1 |
| Rodby, RA | 1 |
| Ritz, E | 1 |
| Aboyans, V | 1 |
| Lacroix, P | 1 |
| Cassat, C | 1 |
| MacGregor, MS | 1 |
| Deighan, CJ | 1 |
| Rodger, RS | 1 |
| Boulton-Jones, JM | 1 |
| Frei, A | 1 |
| Burnier, M | 1 |
| Hess, B | 1 |
| Hanyu, H | 1 |
| Hirao, K | 1 |
| Shimizu, S | 1 |
| Sato, T | 1 |
| Kiuchi, A | 1 |
| Iwamoto, T | 1 |
| Yee, J | 1 |
| Pepin, S | 1 |
| Pitha-Rowe, I | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| Henderson, J | 1 |
| Fox, KM | 1 |
| Liu, PP | 1 |
| Mak, S | 1 |
| Stewart, DJ | 1 |
| Zannad, F | 1 |
| Tulenko, TN | 1 |
| Sumner, AE | 1 |
| Chen, M | 1 |
| Huang, Y | 1 |
| Laury-Kleintop, L | 1 |
| Ferdinand, FD | 1 |
| Eleuteri, E | 1 |
| Goldstein, MR | 1 |
| Pieper, JA | 1 |
| Nishikawa, N | 1 |
| Masuyama, T | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Miwa, T | 1 |
| Sugawara, M | 1 |
| Hori, M | 1 |
| Williams, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [NCT01738945] | Phase 4 | 32 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
7 reviews available for amlodipine and Disease Exacerbation
| Article | Year |
|---|---|
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa | 2014 |
Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2015 |
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com | 2002 |
Potential role of the microvasculature in progression of heart failure.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiomyopathy, Dilated; Coronary Vessels; Disease Mo | 1999 |
Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
Topics: Amlodipine; Calcium Channel Blockers; Carotid Artery Diseases; Coronary Angiography; Coronary Artery | 2000 |
The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection.
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cell Membrane; Cell Membra | 2001 |
Management of coronary heart disease risk factors and progression with calcium channel blockers.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Ar | 2001 |
15 trials available for amlodipine and Disease Exacerbation
| Article | Year |
|---|---|
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P | 2017 |
Effects of additional vasodilatory or nonvasodilatory treatment on renal function, vascular resistance and oxygenation in chronic kidney disease: a randomized clinical trial.
Topics: Amlodipine; Angiotensins; Antihypertensive Agents; Disease Progression; Glomerular Filtration Rate; | 2019 |
Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2013 |
Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Angiography; Coronary Ar | 2015 |
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type | 2014 |
Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosi | 2017 |
Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Dihydropyridine | 2009 |
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Coronary Artery Disease | 2009 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study.
Topics: Amlodipine; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Corona | 2012 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blocker | 2005 |
Nilvadipine prevents cognitive decline of patients with mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Cognition Disorders; D | 2007 |
[Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
Topics: Amlodipine; Arteriosclerosis; Calcium Channel Blockers; Disease Progression; Echocardiography; Human | 2000 |
22 other studies available for amlodipine and Disease Exacerbation
| Article | Year |
|---|---|
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experime | 2018 |
TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Dis | 2015 |
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Dialysis Solu | 2008 |
Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Topics: Adult; Amlodipine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedu | 2009 |
Composite renal endpoints: was ACCOMPLISH accomplished?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2010 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; B | 2013 |
Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
Topics: Amlodipine; Calcium Channel Blockers; Coronary Angiography; Coronary Artery Disease; Disease Progres | 2002 |
Antihypertensive drugs and renal protection.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2005 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
Stepwise decline in visual field after serial sildenafil use.
Topics: Amlodipine; Antihypertensive Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Int | 2008 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |
Can calcium antagonists reverse atherosclerosis?
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Humans | 1999 |
[Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arteriosclerosis; Calcium Channel Blockers; Disease Prog | 2001 |
Does amlodipine increase cancer incidence?
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Humans; Incidenc | 2001 |
Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Antihypertensive Agents; Calcium Channel Blockers; Collag | 2001 |
Amlodipine PREVENTS angina, not atherosclerosis.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Artery Disease; Coronary Disease; Di | 2002 |